SCHEMBL3549228

SCHEMBL3549228

CCCc1cc(C(=O)c2ccc(OC)cc2)ccc1Oc1cccc(C(C)=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 2/20 0.48
MTNR1B P49286 1/20 0.47
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.47
PPARG P37231 3/20 0.45
PPARD Q03181 3/20 0.45
PPARA Q07869 3/20 0.45
LTB4R Q15722 2/20 0.44
LTB4R2 Q9NPC1 2/20 0.44
FOS P01100 1/20 0.43
JUN P05412 1/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
TP53 P04637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
DRD3 P35462 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3544496 0.81 ALDH1A1 (0.44) STSMTNR1BALDH1A1GAAPPARG
SCHEMBL3544497 0.81 ALDH1A1 (0.44) STSMTNR1BALDH1A1GAAPPARG
SCHEMBL3552987 0.77 PPARG (0.41) STSMTNR1BALDH1A1GAAPPARG
SCHEMBL3547512 0.77 PPARG (0.41) STSMTNR1BALDH1A1GAAPPARG
SCHEMBL3548517 0.76 PPARG (0.40) STSMTNR1BALDH1A1GAAPPARG
SCHEMBL6343700 0.76 ALDH1A1 (0.65) ALDH1A1GAAPOLBMEN1KMT2A
SCHEMBL3551254 0.75 PPARG (0.41) STSMTNR1BPPARGPPARDPPARA
SCHEMBL18758803 0.75 MEN1 (0.59) MTNR1BALDH1A1TP53RXFP1NPC1
SCHEMBL2303699 0.75 STS (0.72) STSMTNR1BALDH1A1GAATP53
SCHEMBL13114560 0.74 ALDH1A1 (0.53) STSMTNR1BALDH1A1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807692-B2 Antidiabetic oxazolidinediones and thiazolidinediones MERCK SHARP & DOHME CORP. (US) 2010-10-05 US disclosed
US-20100168164-A1 Antidiabetic Oxazolidinediones and Thiazolidinediones MERCK SHARP & DOHME CORP. 2010-07-01 US disclosed
EP-1907381-A4 ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES MERCK & CO INC (US) 2009-08-26 EP disclosed
EP-1907381-A1 ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES Merck & Co., Inc. (US) 2008-04-09 EP disclosed
WO-2007008501-A1 ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168164-A1 Antidiabetic Oxazolidinediones and Thiazolidinediones PPARD, PPARA, PPARG STS 3296/4885MTNR1B 119/4885ALDH1A1 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.